{
  "OPTISAGE": {
    "AML": "acute myeloid leukemia",
    "RIC": "reduced intensity conditioning",
    "EFS": "event free survival",
    "GVL": "graft versus leukemia",
    "ATG": "Anti thymocyte globulins",
    "MUD": "matched unrelated donor",
    "GRFS": "GVHD relapse free survival"
  },
  "MSC-SLE": {
    "SLE": "Systemic Lupus Erythematosus",
    "AD": "auto Disease",
    "MSC": "Mesenchymal Stem cells",
    "WHO": "World Health Organization",
    "MCR": "Major Clinical Response"
  },
  "CAALLF01": {
    "ALL": "acute lymphoblastic leukemia",
    "ASNase": "asparaginase",
    "DI": "delayed intensifications",
    "MRD": "Minimal Residual Disease",
    "TLP": "traumatic lumbar puncture",
    "GPR": "Good prednisone response",
    "PPR": "Poor Prednisone response"
  },
  "HAPLO-EMPTY": {
    "SAA": "severe aplastic anemia",
    "MUD": "matched unrelated donor",
    "ELT": "eltrombopag",
    "PNH": "paroxysmal nocturnal hemoglobinuria",
    "AML": "acute myeloid leukemia",
    "HSCT": "Hematopoietic stem cell transplantation",
    "GvHD": "Graft versus Host Disease",
    "OS": "overall survival"
  },
  "KAPVEC": {
    "KS": "Kaposi sarcoma",
    "MCC": "Merkel cell carcinoma",
    "BORR": "best overall response rate"
  },
  "FIBRAPLO": {
    "OS": "overall survival",
    "DFS": "disease free survival"
  },
  "SONIMEL": {
    "BBB": "Blood Brain Barrier",
    "US": "UltraSound",
    "MSD": "most successful dose",
    "ECOG": "Eastern Cooperative Oncology Group",
    "PS": "performance status"
  },
  "PARADISE": {
    "PCC": "PillCam Crohn Capsule",
    "CDED": "Crohn Disease Exclusion Diet"
  },
  "MARVEL": {
    "DME": "drug metabolizing enzymes",
    "MAR": "missing at random",
    "ODV": "ODemethylV"
  },
  "DREPA-RIC": {
    "SCD": "sickle cell disease",
    "HSCT": "hematopoietic stem cell transplantation",
    "MRD": "matched related donor",
    "GVHD": "graft versus host disease",
    "TBI": "total body irradiation",
    "CT": "computed tomography",
    "TP": "transfusion program",
    "GFR": "glomerular fraction rate"
  },
  "PIPAC": {
    "QoL": "quality of life",
    "CI": "Confidence Intervals"
  },
  "JAKAHDI": {
    "HS": "Hemophagocytic syndrome"
  },
  "METIMGAST": {
    "ORR": "overall response rate",
    "HIV": "Human Immunodeficiency Virus",
    "CNS": "central nervous system"
  },
  "RUBI": {
    "BCVA": "best corrected visual acuity",
    "NIU": "Non infectious Uveitis",
    "OCT": "ocular coherence tomography",
    "CME": "cystoid macular edema",
    "MAMS": "Multi Arm Multi Stage"
  },
  "EFRAIM-II": {
    "ARF": "Acute respiratory failure",
    "DNI": "Do Not Intubate",
    "DNR": "Do Not Resuscitate"
  },
  "UVB": {
    "BCVA": "best corrected visual acuity",
    "ICBD": "International Criteria Behçet Disease",
    "OCT": "Optical Coherence Tomography"
  },
  "MSC-AT-SSC": {
    "AD": "autoimmune disease",
    "AHSCT": "autologous hematopoietic stem cell transplantation",
    "MSC": "Mesenchymal stromal cells",
    "IV": "intravenous",
    "TRSAE": "treatment related Severe Adverse Events",
    "SAE": "Severe Adverse Events",
    "AE": "Adverse Events",
    "CTCAE": "Common Terminology Criteria Adverse Events",
    "PFS": "Progression free survival",
    "GRCS": "Global Rank Composite Score",
    "DSMB": "Data Safety Monitoring Board"
  },
  "INTORETAK": {
    "TA": "Takayasu arteritis",
    "CS": "corticosteroids",
    "ACR": "American College Rheumatology",
    "HIV": "human immunodeficiency virus"
  },
  "TRIBECA": {
    "WCBP": "Women Child Bearing Potential"
  },
  "PCL-2": {
    "pPCL": "Primary plasma cell leukemia",
    "OS": "overall survival",
    "MM": "multiple myeloma",
    "MRD": "minimal residual disease",
    "TEAE": "Treatment Emergent Adverse Event",
    "SAE": "Serious Adverse Event",
    "NCI": "National Cancer Institute",
    "ECOG": "Eastern Cooperative Oncology Group",
    "ULN": "upper limit normal",
    "PCR": "polymerase chain reaction",
    "HBV": "hepatitis B virus",
    "GCP": "good clinical practice",
    "ICH": "International Conference Harmonization"
  },
  "ITAC": {
    "BD": "Behçet disease"
  },
  "FOCUS": {
    "NIU": "non infectiuous uveitis",
    "BCVA": "best corrected visual acuity",
    "OCT": "optical coherence tomographic",
    "GFR": "Glomerular filtration rates",
    "NYHA": "New York Heart Association"
  },
  "ICE": {
    "MC": "mixed cryoglobulinaemia",
    "MGUS": "monoclonal gammapathy unknown significance",
    "BVAS": "Birmingham Vasculitis Activity Score"
  },
  "GRAALL-2014": {
    "SR": "Standard risk",
    "HR": "high risk",
    "CIR": "cumulative incidence relapse",
    "NRM": "non relapse mortality",
    "DFS": "disease free survival",
    "OS": "overall survival",
    "CNS": "central nervous system",
    "SAEs": "Serious adverse events"
  },
  "MAC-HAPLO-MUD": {
    "SCT": "stem cell transplantation",
    "MUD": "matched unrelated donors",
    "PBSC": "Peripheral blood stem cell",
    "HR": "Hazard ratio"
  },
  "SHORTCUT": {
    "KTR": "kidney transplant recipients",
    "UTI": "urinary tract infection",
    "MDR": "Multidrug"
  },
  "CAMOVID": {
    "RTPCR": "reverse transcription polymerase chain reaction",
    "AEs": "Adverse events",
    "GPs": "general practitioners",
    "GHSIF": "Groupe Hospitalier Sud Ile France"
  },
  "GREEN": {
    "AIS": "acute ischemic stroke",
    "SAEs": "serious adverse events",
    "SUSARs": "suspected unexpected serious adverse reactions",
    "BREs": "bleeding related events",
    "LVO": "large vessel occlusion",
    "ICA": "internal carotid artery",
    "DAPT": "dual anti platelet therapy"
  },
  "TEOREM": {
    "CD": "Crohn disease",
    "AIEC": "adherent invasive E coli"
  },
  "SALMA": {
    "AML": "Acute Myeloid Leukemias",
    "SOC": "standard of care",
    "HSCT": "hematopoietic stem cell transplantation",
    "IDA": "idarubicin",
    "CR": "complete remission",
    "ED": "early date",
    "EFS": "event free survival",
    "DLTs": "dose limiting toxicities",
    "MTD": "maximal tolerated dose",
    "SSZ": "Sulfasalazine",
    "DLT": "dose limiting toxicity",
    "PK": "pharmacokinetics",
    "PD": "pharmacodynamics",
    "EOI": "end of induction",
    "AE": "Adverse events",
    "TEAE": "treatment emergent adverse events",
    "SAEs": "serious adverse events",
    "DSMB": "data safety monitoring board",
    "ULN": "upper limit normal",
    "GFR": "glomerular filtration rate",
    "DL": "dose levels",
    "MRD": "minimal residual disease",
    "CRM": "continual reassessment method"
  },
  "ERYTHROSIM": {
    "PRCA": "pure red cell aplasia"
  },
  "RECORDS": {
    "CS": "corticosteroids",
    "ICU": "intensive care unit"
  },
  "KAPKEY": {
    "KS": "Kaposi sarcoma",
    "BORR": "Best Overall Response Rate",
    "CTCAE": "Common Terminology Criteria Adverse Events",
    "ANC": "Absolute neutrophil count"
  },
  "UPFRONT-MUD": {
    "AA": "aplastic anemia",
    "FFS": "failure free survival",
    "MUD": "matched unrelated donor",
    "HSCT": "hematopoietic stem cell transplantation",
    "GvHD": "Graft versus Host Disease"
  },
  "HAPLORESCUE": {
    "DSA": "donor specific antibody"
  },
  "FIRST": {
    "OS": "Overall Survival",
    "DFS": "disease free survival",
    "NRM": "Non relapse mortality",
    "BMI": "Body Mass Index",
    "PBSC": "peripheral blood stem cell",
    "CR": "complete remission"
  },
  "APARR": {
    "HSCT": "Hematopoietic Stem Cell Transplantation",
    "AA": "aplastic anemia",
    "EPAG": "eltrombopag",
    "PNH": "paroxysmal nocturnal hemoglobinuria",
    "AML": "acute myeloid leukemia",
    "GvHD": "graft versus host disease"
  }
}